Patent intelligence · US
US 8007774
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
Patent details — US 8007774
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 30, 2011
- Expiration
- Aug 25, 2031
- Applicant
- REGENTIS BIOMATERIALS LTD.
- Claims
- 8
- CPC classes
- A61K, A61K38/363, A61K38/39, A61K38/45
Quick answer
US 8007774 (Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same) is held by REGENTIS BIOMATERIALS LTD.. Status: granted. Granted Aug 30, 2011. Expires Aug 25, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENTIS BIOMATERIALS LTD.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K38/363, A61K38/39, A61K38/45, A61K47/60, A61K47/6435
More from REGENTIS BIOMATERIALS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8007774?
US 8007774 (Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same) is held by REGENTIS BIOMATERIALS LTD.. Status: granted. Granted Aug 30, 2011. Expires Aug 25, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8007774?
REGENTIS BIOMATERIALS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8007774 expire?
Our index shows an expiration date of Aug 25, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.